不过Blakney认为,“这不失为一种可行的策略,但还有很多需要完善和检验的地方”。 用mRNA技术对抗癌症则是通过一种叫做“癌症疫苗”(cancer vaccine)的法疗来实现的。癌症疫苗的总体思路是让一个人的免疫系统可以精准区分肿瘤细胞和正常细胞,通过将肿瘤抗原以多种形式(如核酸、蛋白多肽等)导入患者体内,来刺激患者体内...
不过Blakney认为,“这不失为一种可行的策略,但还有很多需要完善和检验的地方。 用mRNA技术对抗癌症则是通过一种叫做“癌症疫苗”(cancer vaccine)的法疗来实现的。癌症疫苗的总体思路是让一个人的免疫系统可以精准区分肿瘤细胞和正常细胞,通过将肿瘤抗原以...
不过Blakney认为,“这不失为一种可行的策略,但还有很多需要完善和检验的地方。 用mRNA技术对抗癌症则是通过一种叫做“癌症疫苗”(cancer vaccine)的法疗来实现的。癌症疫苗的总体思路是让一个人的免疫系统可以精准区分肿瘤细胞和正常细胞,通过将肿瘤抗原以多种形式(如核酸、蛋白多肽等)导入患者体内,来刺激患者体内自...
Furthermore, many earlyphase trials testing a wide range of vaccine designs are currently ongoing. In this Review, we describe the advantages of cancer mRNA vaccines and advances in clinical trials using both cell-based and nanoparticle-based delivery methods, with discussions of future combinations ...
Meng Wenjun, Peng Xingchen. Research status, challenges, and prospects of mRNA-based cancer vaccine. Journal of Practical Oncology, 2023, 38(3): 218-221. 癌症种类繁多,一直是危害人类健康的最主要疾病之一。手术和放化疗目前仍是治疗各类癌种的支柱方法,特...
用mRNA技术对抗癌症则是通过一种叫做“癌症疫苗”（cancer vaccine）的法疗来实现的。癌症疫苗的总体思路是让一个人的免疫系统可以精准区分肿瘤细胞和正常细胞，通过将肿瘤抗原以多种形式（如核酸、蛋白多肽等）导入患者体内，来刺激患者体内自身免疫系统的反应从而对肿瘤细胞进行清除。由于不同癌症患者的肿瘤细胞突变不同...
虹信生物基于组合化学开发的、以1,2-二酯为核心骨架的新型可离子化氨基脂质能够实现快速肝清除,并安全、有效地实现mRNA递送,研究成果以题为“Delivery of mRNA Vaccine with 1, 2-Diesters-Derived Lipids Elicits Fast Liver Clearance for Safe and Effective Cancer Immunotherapy”发表在行业顶刊Advanced Healthcare...
vaccine platforms against infectious diseases and several types of cancer have demonstrated encouraging results in both animal models and humans. This Review provides a detailed overview of mRNA vaccines and considers future directions and challenges in advancing this promising vaccine platform to widespread...
新抗原mRNA疫苗——癌症治疗领域可行性新方法 持续的新冠疫情凸显了疫苗的重要性，目前两款最有效的新冠疫苗均是基于mRNA技术， mRNA疫苗以其在医学领域的广阔前景而荣登《MIT Technology Review》 2021年“全球十大突破性技术”榜首，有望在癌症治疗领域大有所为。20世纪90年代中期，Martinon 和Conry 两位前辈率先验证了...
Furthermore, many earlyphase trials testing a wide range of vaccine designs are currently ongoing. In this Review, we describe the advantages of cancer mRNA vaccines and advances in clinical trials using both cell-based and nanoparticle-based delivery methods, with discussions of future combinations ...